[TREATMENT OF BLADDER UROTHELIAL CARCINOMA WITH LUNG METASTASIS AFTER RENAL TRANSPLANTATION]. 2022

Tatsu Tanabe, and Takahiro Osawa, and Kiyohiko Hotta, and Daiki Iwami, and Hiroshi Kikuchi, and Ryuji Matsumoto, and Takashige Abe, and Nobuo Shinohara
Department of Urology, Hokkaido University Hospital.

We report a case of bladder cancer in a 54-year-old woman who underwent renal transplantation for chronic renal failure. Six years after the transplantation, she was diagnosed with muscle-invasive bladder cancer with multiple lung metastases. She received gemcitabine/cisplatin therapy for Stage IV bladder cancer, and the dose of the immunosuppressants was reduced to prevent adverse effects. Since lung metastatic lesions disappeared after four courses of chemotherapy and no new lesions were found, we performed radical cystectomy and right nephroureterectomy with ileal conduit construction. Although she was followed closely without therapy, multiple lung metastases appeared 6 months after the radical cystectomy. Gemcitabine/carboplatin therapy was administered, and the lung metastasis improved slightly until the end of the 4th course, but aggressive growth was observed after the 5th course. She switched to palliative treatment without requesting additional treatment and died of cancer 1 year and 9 months after total cystectomy.There is no evidence-based treatment strategy for advanced bladder cancer after kidney transplantation. It is necessary to recognize that the patient had renal dysfunction and was in an immunosuppressed state. Thus, it is crucial to select appropriate drug and surgical treatments for each patient.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001743 Urinary Bladder A musculomembranous sac along the URINARY TRACT. URINE flows from the KIDNEYS into the bladder via the ureters (URETER), and is held there until URINATION. Bladder,Bladder Detrusor Muscle,Detrusor Urinae,Bladder Detrusor Muscles,Bladder, Urinary,Detrusor Muscle, Bladder,Detrusor Muscles, Bladder
D001749 Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER. Bladder Cancer,Bladder Neoplasms,Cancer of Bladder,Bladder Tumors,Cancer of the Bladder,Malignant Tumor of Urinary Bladder,Neoplasms, Bladder,Urinary Bladder Cancer,Bladder Cancers,Bladder Neoplasm,Bladder Tumor,Cancer, Bladder,Cancer, Urinary Bladder,Neoplasm, Bladder,Neoplasm, Urinary Bladder,Tumor, Bladder,Tumors, Bladder,Urinary Bladder Neoplasm
D002295 Carcinoma, Transitional Cell A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS. Carcinomas, Transitional Cell,Cell Carcinoma, Transitional,Cell Carcinomas, Transitional,Transitional Cell Carcinoma,Transitional Cell Carcinomas
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000093542 Gemcitabine A deoxycytidine antimetabolite used as an antineoplastic agent. 2',2'-Difluoro-2'-Deoxycytidine,2',2'-Difluorodeoxycytidine,2'-Deoxy-2',2''-Difluorocytidine-5'-O-Monophosphate,2'-Deoxy-2'-Difluorocytidine,Gemcitabine Hydrochloride,Gemcitabine, (D-threo-pentafuranosyl)-Isomer,Gemcitabine, (alpha-D-threo-pentofuranosyl)-Isomer,Gemcitabine, (beta-D-threo-pentafuranosyl)-Isomer,Gemicitabine,2',2'-DFDC,Gemzar,LY 188011,LY-188011,dFdCyd,188011, LY,2' Deoxy 2' Difluorocytidine,2' Deoxy 2',2'' Difluorocytidine 5' O Monophosphate,Hydrochloride, Gemcitabine
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy

Related Publications

Tatsu Tanabe, and Takahiro Osawa, and Kiyohiko Hotta, and Daiki Iwami, and Hiroshi Kikuchi, and Ryuji Matsumoto, and Takashige Abe, and Nobuo Shinohara
August 2019, Journal of medical cases,
Tatsu Tanabe, and Takahiro Osawa, and Kiyohiko Hotta, and Daiki Iwami, and Hiroshi Kikuchi, and Ryuji Matsumoto, and Takashige Abe, and Nobuo Shinohara
January 2020, Urology case reports,
Tatsu Tanabe, and Takahiro Osawa, and Kiyohiko Hotta, and Daiki Iwami, and Hiroshi Kikuchi, and Ryuji Matsumoto, and Takashige Abe, and Nobuo Shinohara
February 2013, Hinyokika kiyo. Acta urologica Japonica,
Tatsu Tanabe, and Takahiro Osawa, and Kiyohiko Hotta, and Daiki Iwami, and Hiroshi Kikuchi, and Ryuji Matsumoto, and Takashige Abe, and Nobuo Shinohara
October 2007, Journal francais d'ophtalmologie,
Tatsu Tanabe, and Takahiro Osawa, and Kiyohiko Hotta, and Daiki Iwami, and Hiroshi Kikuchi, and Ryuji Matsumoto, and Takashige Abe, and Nobuo Shinohara
November 2008, British journal of cancer,
Tatsu Tanabe, and Takahiro Osawa, and Kiyohiko Hotta, and Daiki Iwami, and Hiroshi Kikuchi, and Ryuji Matsumoto, and Takashige Abe, and Nobuo Shinohara
March 2022, IJU case reports,
Tatsu Tanabe, and Takahiro Osawa, and Kiyohiko Hotta, and Daiki Iwami, and Hiroshi Kikuchi, and Ryuji Matsumoto, and Takashige Abe, and Nobuo Shinohara
August 2020, Future science OA,
Tatsu Tanabe, and Takahiro Osawa, and Kiyohiko Hotta, and Daiki Iwami, and Hiroshi Kikuchi, and Ryuji Matsumoto, and Takashige Abe, and Nobuo Shinohara
May 2020, Cureus,
Tatsu Tanabe, and Takahiro Osawa, and Kiyohiko Hotta, and Daiki Iwami, and Hiroshi Kikuchi, and Ryuji Matsumoto, and Takashige Abe, and Nobuo Shinohara
December 2004, Archivos espanoles de urologia,
Tatsu Tanabe, and Takahiro Osawa, and Kiyohiko Hotta, and Daiki Iwami, and Hiroshi Kikuchi, and Ryuji Matsumoto, and Takashige Abe, and Nobuo Shinohara
September 2011, International urology and nephrology,
Copied contents to your clipboard!